	US 11,938,101 B2
	Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
Paul Mollard, Mountain View, CA (US); Peter Giannousis, Mountain View, CA (US); Shazad Suchit, Devens, MA (US); Mahmoud Mirmehrabi, Halifax (CA); Christopher R. Cornell, Mountain View, CA (US); and Kieron E. Wesson, Mountain View, CA (US)
Assigned to PTC THERAPEUTICS, INC., South Plainfield, NJ (US)
Filed by PTC Therapeutics, Inc., South Plainfield, NJ (US)
Filed on Mar. 10, 2022, as Appl. No. 17/692,133.
Application 17/692,133 is a continuation of application No. 16/919,044, filed on Jul. 1, 2020, granted, now 11,304,914.
Application 16/919,044 is a continuation of application No. 16/354,070, filed on Mar. 14, 2019, granted, now 10,751,302, issued on Aug. 25, 2020.
Application 16/354,070 is a continuation of application No. 15/536,603, granted, now 10,251,847, issued on Apr. 9, 2019, previously published as PCT/US2015/066211, filed on Dec. 16, 2015.
Claims priority of provisional application 62/133,276, filed on Mar. 13, 2015.
Claims priority of provisional application 62/092,743, filed on Dec. 16, 2014.
Prior Publication US 2022/0265578 A1, Aug. 25, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 235/78 (2006.01); A61K 31/122 (2006.01); A61K 31/164 (2006.01); C07B 57/00 (2006.01); C07C 215/08 (2006.01); C07C 215/28 (2006.01); C07C 215/30 (2006.01); C07C 231/12 (2006.01); C07D 215/28 (2006.01)

CPC A61K 31/122 (2013.01) [A61K 31/164 (2013.01); C07B 57/00 (2013.01); C07C 215/08 (2013.01); C07C 215/28 (2013.01); C07C 215/30 (2013.01); C07C 231/12 (2013.01); C07C 235/78 (2013.01); C07B 2200/13 (2013.01); C07C 2601/16 (2017.05)]

13 Claims

1. A composition comprising a polymorph of an anhydrate, a hydrate, or a solvate of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide, wherein the composition comprises a polymorph Form I and at least one polymorph selected from the group consisting of Form II, Form III, Form IV, Form V, and Form VI;

wherein a powder X-ray diffraction pattern for polymorph Form I comprises characteristic peaks at least at the following angular positions, wherein the angular positions may vary by ±0.2: 12.06, 15.33, 17.03, and 17.26;

wherein a powder X-ray diffraction pattern for polymorph Form V comprises characteristic peaks at least at the following angular positions, wherein the angular positions may vary by ±0.2: 9.61, 11.49, 12.93, and 15.45;

wherein a powder X-ray diffraction pattern for polymorph Form III comprises characteristic peaks at least at the following angular positions, wherein the angular positions may vary by ±0.2: 9.16, 14.02, 15.23, and 21.10;

wherein a powder X-ray diffraction pattern for polymorph Form II comprises characteristic peaks at least at the following angular positions, wherein the angular positions may vary by ±0.2: 9.63, 10.85, 11.33, and 19.33;

wherein a powder X-ray diffraction pattern for polymorph Form IV comprises characteristic peaks at least at the following angular positions, wherein the angular positions may vary by ±0.2: 4.31, 8.76, 12.97, and 13.20; and

wherein a powder X-ray diffraction pattern for polymorph Form VI comprises characteristic peaks at least at the following angular positions, wherein the angular positions may vary by ±0.2: 6.27, 9.91, 12.94, and 15.71.